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Introduction
The ever widening disparity between the demand for kidneys for transplantation and their availability from suitable donors continues to challenge the professional view of what is acceptable as a suitable donor, with growing interest particularly notable in donors after circulatory death, which now constitute more than 30% of deceased organ donors in the United Kingdom. Although it is now well established that long-term function from mus due to acute rejection or intolerable drug side effects. Conclusions: Graft survival and function were very similar in the two groups despite the higher rate of acute rejection in the sirolimus arm, raising the possibility that the damage done by acute rejection was adequately offset by the nephron-sparing effect of sirolimus compared to tacrolimus. Sirolimus may have a role as a longer-term maintenance immunosuppressant after initial treatment with a different agent such as tacrolimus or belatacept.
Curr Urol 2013;7: [174] [175] [176] [177] [178] [179] [180] Sirolimus versus Tacrolimus following Kidney Transplantation 175 such donors is comparable to heart-beating donors after brain death [1, 2] , even in cases of uncontrolled donation [3] , early results tend to be inferior with increased rates of delayed graft function [4, 5] and primary non-function [6] . Delayed graft function to increased duration of hospital stay together with the risk of morbidity from dialysis, renal biopsies and healthcare-associated infection, while primary non-function results in patients who are sensitised as well as causing technical difficulties with access to vessels for re-transplantation.
The inferior early function in kidneys from donors after circulatory death is presumably a function of the increased ischaemia-reperfusion injury experienced by these kidneys, which the authors believe to be due to increased ischaemia arising from three separate factors. The first factor is pre-mortem renal hypoperfusion, due to hypotension in the agonal phase before cardiac arrest in both controlled and uncontrolled donors and the decreased cardiac output during cardiopulmonary resuscitation attempts in uncontrolled donors [7] . The second factor is the primary warm ischaemia between cardiac arrest and cold perfusion, and the third is the cold ischaemic time, which can be minimised by use of such manoeuvres as virtual crossmatching [8, 9] and retaining donor/donation after circulatory death (DCD) organs for local implantation. The increased ischaemia-reperfusion injury can be expected to increase the risk of acute tubular necrosis within the transplanted kidney, as well as endothelial injury leading to leakage and sequestration of pro-inflammatory mediators within the renal allograft. These deleterious effects may be exacerbated by further insults to the graft during the post-operative phase, including dehydration and nephrotoxic drugs, which are therefore avoided where possible.
Among the nephrotoxic drugs difficult to avoid are the calcineurin-inhibitors which so revolutionised the results of transplantation by their effectiveness in preventing and attenuating acute rejection. Among their side-effects is the promotion of vasoconstriction of the glomerular arterioles, increasing intra-renal resistance and reducing effective perfusion of the graft [10] [11] [12] . Strategies to minimise or avoid exposure to calcineurin-inhibitors in the immediate post-transplant period might therefore be expected to improve short-term outcome in DCD kidney transplantation, and indeed a prospective trial of using IL-2 receptor blockade to permit delayed introduction of calcineurin-inhibition in DCD kidneys has been published [13] .
The mTOR inhibitor sirolimus, by providing an immunosuppressant effect similar to the calcineurin inhibitors without nephrotoxic side effects [14] [15] [16] , raised the enticing possibility of effective prophylaxis against rejection without compromise in function, and has been studied in numerous clinical trials. Although not nephrotoxic, sirolimus has been shown to delay recovery of function in the transplanted kidney exposed to ischemia-reperfusion injury [17] , so a delayed introduction might prove advantageous. The Rapamycin Maintenance Regime trial showed improved GFR at 12 months where cyclosporin was withdrawn from a regime including sirolimus and steroids compared to a group where the cyclosporin was continued [15] . Flechner et al. [18] showed improved GFR at both 6 and 12 months when sirolimus was used to replace ciclosporin completely in a regime which also included induction therapy with basiliximab and maintenance treatment with mycophenolate mofetil. Based upon Flechner's study and our earlier work, we decided to conduct a study to assess the impact on transplant renal function of sirolimus versus tacrolimus, after delayed introduction, in DCD kidney transplantation.
Methods
We conducted a prospective randomised paired open-label study to compare the renal function in recipients receiving sirolimus or tacrolimus as maintenance immunosuppressants after DCD kidney transplantation.
Inclusion/Exclusion Criteria
We included all pairs of kidneys from locally retrieved donors after circulatory death. Pairs were excluded from the study if performed as a dual implant into one recipient, and individual kidneys were excluded if there was lack of patient consent to enrolment, if the kidney had failed prior to randomisation (from primary non-function or renal vein thrombosis), or if the patient was withdrawn from the trial due to side effects of the allocated treatment.
Protocol
To prevent increase in the duration of cold ischaemia arising from organ transportation, it is currently practice in the United Kingdom that DCD kidneys are retained locally for implantation, and thus we were able to obtain two kidneys from each donor, allowing a paired study.
Induction therapy was used in all patients in the form a single 2 mg/kg dose of the IL-2 receptor blocking antibody daclizumab administered intravenously at the time of induction of general anaesthesia. Additionally, a 500mg intravenous dose of methylprednisolone was administered at the time of starting the arterial anastomosis.
Initial immunosuppression took the form of 20mg oral prednisolone and 2 g/day oral mycophenolate mofetil, starting as 1g twice daily but with the option to change to 500mg four times daily if gastrointestinal side effects occurred, as unit experience suggests that such side effects are reduced by this dosage change.
Asher/Vasdev/Wyrley-Birch/Wilson/ Soomro/Rix/Jaques/Manas/Torpey/Talbot One kidney from each pair was randomised to a delayed introduction of tacrolimus and the other to a delayed introduction of sirolimus. The delayed introduction was defined as once the serum creatinine was less than 350 µmol/l (3.96 mg/dl) or on the 10th postoperative day, whichever occurred first. Tacrolimus was administered as Prograf, with starting dose of 0.05 mg/kg twice daily, titrated to achieve a trough serum concentration of 5-10 ng/ml. Sirolimus was started at 2 mg/day and the dosage was adjusted to achieve a trough level of 5-10 mg/day. This was later modified slightly to a target of 8-10 mg/day. One kidney was generally implanted first and therefore of a pair one had a shorter cold ischaemic time than the other. The randomisation was designed so that there was an equal number of 'first' transplants for each drug. Once tacrolimus or sirolimus was started, the mycophenolate mofetil dose was reduced to 1 g/day and prednisolone gradually reduced as per the normal unit protocol.
Outcome Measures
The primary endpoint of the study was renal function post-transplant, with creatinine clearance estimated by the Cockcroft-Gault formula. The rate of biopsy-proven acute rejection and patient and graft survival were secondary endpoints.
Statistical Analysis
Statistical analysis was performed using SPSS. Continuous variables were compared with the Wilcoxon sign rank test as a paired, non-parametric test, and categorical variables compared with the Chi-square test. A two-tailed p value of less than 0.05 was considered to demonstrate a statistically-significant difference.
As switches between the immunosuppressants due to side effects were expected, the primary endpoint of graft function was analysed both on an intention to treat and per protocol basis.
To achieve a power of 80% with an alpha of 0.05 for a 15 ml/min difference in creatinine clearance, we calculated that we would need at least 30 patients in each group, based on the results of Flechner's study [18] . 
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Results
Total 31 donor kidney pairs were planned for the trial, giving 31 kidneys in each group. Six patients were withdrawn from each group (3 renal vein thrombosis, 1 primary non-function, 1 death prior to hospital discharge and 1 non-used partner kidney in the tacrolimus group; 2 drug side effects, 2 acute rejection prior to randomisation, 1 lack of consent and 1 persisting acute tubular necrosis in the sirolimus group), resulting in the withdrawal of 12 pairs from the study and hence a total of 12 patients in each group. The exclusions are shown in table 1.
The 2 groups were well matched for recipient age and median ischaemic time. All were first transplant patients and none were re-transplants. More of the patients in the sirolimus groups were pre-emptive transplants prior to commencing dialysis (26 vs. 5%), and there were more CMV donor positive to recipient negative mismatches in the tacrolimus group. Recipient characteristics are shown in table 2.
Ten of the 19 patients in the sirolimus group were switched to tacrolimus during the follow-up period of the study. The median time to switch was 2.5 months (range 1-11 months); 5 were switched for biopsy-proven acute rejection, of which all were within 3 months, 1 was switched for graft dysfunction at 4 months and the other 4 were switched due to side effects. None of the tacrolimus patients were switched to sirolimus. Switches are detailed in table 3.
There were no statistically significant differences in median serum creatinine or calculated creatinine clearance between the two groups, either in the intention to treat or per protocol analysis. The graft function is shown in table 4 (intention to treat) and table 5 (per protocol).
Biopsy proven acute rejection occurred in 5 of the 19 patients randomised to sirolimus (26%) and 2 of the 19 patients randomised to tacrolimus (11%). Sirolimus levels at the time of rejection were 5.4 ng/ml for the first recipient, 3.8 and 7.0 at the time of the first 2 biopsies for the second recipient, 8.8 and 13.7 at the time of both biopsies for the third recipient and 5.8 and 16.3 ng/ml for the last 2 recipients respectively (according to the order of the recipients in table 3). Rejection occurred prior to starting tacrolimus in both recipients. The difference in rejection rate was not statistically significant (c 2 = 0.700, p = 0.403). Both patient and graft survival at one year were 100% in the tacrolimus group, while there was one death with functioning graft in the sirolimus group (95% survival).
Discussion
The introduction of ciclosporin-based immunosuppression revolutionised transplantation, and can be said to the key milestone demarcating the boundary between the experimental era and the era of transplantation as routine, having largely solved the hitherto intractable problem of acute rejection. The impairment of longterm function has been cyclosporin's Achilles heel, but a problem the transplant surgeons of the 1970s would have welcomed as almost trivial compared to the burden of rejection seen in that era. Although perhaps easier to dose accurately, tacrolimus offers the same advantages and causes the same problems as ciclosporin. The CAE-SAR trial reinforced the value calcineurin inhibitors, showing increased rates of rejection in calcineurin inhibitor withdrawal [19] . As a non-nephrotoxic [16] drug offering immunosuppression by a similar mechanism to the calcineurin inhibitors, sirolimus appeared to exhibit an enticing potential to be immunosuppressant of choice, especially as it is associated with a lower incidence of Asher/Vasdev/Wyrley-Birch/Wilson/ Soomro/Rix/Jaques/Manas/Torpey/Talbot GFR is the creatinine clearance as estimated by the Cockcroft-Gault formula. None of these differences were statistically significant.
Of the 19 patients in the sirolimus group, 10 were switched to tacrolimus and thus excluded from this analysis; the numbers of sirolimus group patients included was 14 at 3 months, 12 at 6 months, 11 at 9 months and 10 at 12 months.
Creatinine µmol/l (mg/dl) GFR (ml/min) [20] [21] [22] [23] , leading to drug switches, and sadly long-term graft function was shown in the ELITE Symphony study inferior to use of low dose tacrolimus-based regimes [24] .
In this trial, we were unable to demonstrate a difference in intermediate-term renal allograft function between use of tacrolimus and sirolimus-based regimes. This may be in part a reflection of power, as once pairs were excluded from the trial we were left with 19 pairs to analyse out of 30 that would be needed to achieve our a priori power estimates, and additionally 10 of the 19 patients in the sirolimus group were excluded from the per protocol analysis as they had been switched to tacrolimus. However, the actual median results were very similar, implying that there was no difference, although this study was not powered for a non-inferiority analysis.
For glomerular filtration rate those patients on sirolimus had an initial improvement of the order of 10.2 ml/ minute (59.7 vs. 69.9) which lasted 6 months and then the GFR declined for the few patients remaining on the sirolimus. This is broadly in line with the recently reported Zeus trial (Budde 2011 ) but a long way short of the difference of 15 as reported by Flechner that this trial was based on. In addition the Zeus trial took patients 4.5 months post transplant after initial cyclosporin, mycophenolate and steroid regime.
The A2309 study reduced calcineurin inhibitors (CNI) over one year in combination with everolimus and though they avoided rejection and adverse effects and achieved a 60% reduction of cyclosporin this did not change graft function. The pilot study of Holdaas of 20 kidney patients switched from cyclosporin to everolimus at week seven achieved an improvement of GFR from 51 to 58 in the short term with a 15% incidence of biopsy proven rejection.
These studies therefore reinforce the findings of this trial that though there is an improvement in GFR at least in the short term with sirolimus or everolimus this did not achieve the levels reported previously. Also most Curr Urol 2013;7:174-180
Sirolimus versus Tacrolimus following Kidney Transplantation 179 trials conducted since the original Flechner study have converted patients from a CNI regime sometime after the early transplant period. Our hope had been to continue from the CNI-free window used routinely in our centre for DCD kidneys to obtain graft recovery and then continue into a completely CNI-free regime. From our increased acute rejection rates it would suggest that either CNI avoidance with just basiliximab was insufficient to cover this period. This could be overcome by either belatacept or alemtuzumab to cover this period of recovery. However the incidence of side effects related to the use of sirolimus and the only marginal improvement of GFR would question the routine early use of sirolimus for all recipients of DCD kidneys [29, 30] .
